⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24495447 | 1.00 | — | — | |
| SCHEMBL14608868 | 1.00 | — | — | |
| SCHEMBL13552263 | 1.00 | — | — | |
| SCHEMBL19372076 | 0.88 | — | — | |
| SCHEMBL10284381 | 0.77 | — | — | |
| SCHEMBL18570016 | 0.76 | — | — | |
| SCHEMBL19050057 | 0.73 | — | — | |
| SCHEMBL3134033 | 0.73 | — | — | |
| SCHEMBL19082598 | 0.73 | — | — | |
| SCHEMBL19071644 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| EP-4008758-B1 | ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO LTD (KR) | 2023-09-06 | — | — | EP | disclosed |
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2023-01-24 | — | — | US | disclosed |
| US-20230010535-A1 | ELECTROACTIVE COMPOUNDS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2023-01-12 | — | — | US | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20220054465-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| EP-3022180-B1 | UV ABSORBING COMPOUNDS, COMPOSITIONS COMPRISING SAME AND USES THEREOF | CORAL SUNSCREEN PTY LTD (AU) | 2022-02-23 | — | — | EP | disclosed |
| US-20220015358-A1 | Encapsulated Biocides | ARXADA AG (CH) | 2022-01-20 | — | — | US | disclosed |
| US-11000515-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-05-11 | — | — | US | disclosed |
| US-10933054-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-03-02 | — | — | US | disclosed |
| US-9598367-B2 | Heterocyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-03-21 | — | — | US | disclosed |
| US-9593124-B2 | Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof | RHODES TECHNOLOGIES (US) | 2017-03-14 | — | — | US | disclosed |
| EP-2327679-B1 | NOVEL ANTHRACENE DERIVATIVES AND ORGANIC ELECTRONIC DEVICE USING SAME | LG CHEMICAL LTD (KR) | 2017-03-01 | — | — | EP | disclosed |
| EP-1561745-B1 | Process for the preparation of di- and polyisocyanates of the diphenylmethane series with defined acidity | COVESTRO DEUTSCHLAND AG (DE) | 2017-03-01 | — | — | EP | disclosed |
| US-9556127-B2 | Diaminopyrimidines as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2017-01-31 | — | — | US | disclosed |
| EP-2221051-A1 | AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONIST ACTIVITY AND USE THEREOF | Shionogi&Co., Ltd. (JP) | 2010-08-25 | — | — | EP | disclosed |
| EP-2140862-A2 | Use of GAL 3 receptor antagonists for the treatment of depression and /or anxiety and compounds useful in such methods | H.Lundbeck A/S (DK) | 2010-01-06 | — | — | EP | disclosed |
| EP-1233948-B1 | STABLE POLYMORPH OF N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE HYDROCHLORIDE, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | OSI PHARM INC (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20080199420-A1 | Cosmetic oil in water emulsion ofamphiphilic polymer with hydrophilic and hydrophobic units formed from polyisobutenes modified with terminal polar groups, emulsifier, oil and water; ethylene oxide-propylene oxide block polymer modified polyisobutenyl succinic anhydride; hydroxylation, epoxidation | BASF AKTIENGESELLSCHAFT (DE) | 2008-08-21 | — | — | US | disclosed |
| WO-2008041053-A2 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2008-04-10 | — | — | WO | disclosed |